GLP-1 clinical practice

GLP-1 Switch — Tirzepatide → Semaglutide

Transition protocol from tirzepatide to semaglutide — typically due to cost, supply, or insurance coverage change. Approximate dose equivalences: tirzepatide 5mg ≈ semaglutide 0.5mg; tirzepatide 10mg ≈ semaglutide 1mg; tirzepatide 15mg ≈ semaglutide 2mg. Expect temporary appetite increase during transition.

Duration

Steps

10

Total Weeks

32

Route

SubQ

Protocols

2

Source

clinical practice

Protocol Timeline

Step Weeks Dose Compound Note
1 4 2.5 mg Tirzepatide Initiation dose — for GI tolerability
2 4 5 mg Tirzepatide First therapeutic dose
3 4 7.5 mg Tirzepatide Increase if additional glycemic control needed
4 4 10 mg Tirzepatide
5 4 12.5 mg Tirzepatide
6 0 15 mg Tirzepatide Maximum dose — maintenance
1 4 0.25 mg Semaglutide (Injectable) Initiation dose — for GI tolerability, not therapeutic
2 4 0.5 mg Semaglutide (Injectable) First therapeutic dose
3 4 1 mg Semaglutide (Injectable) Standard target dose — increase if additional glycemic control needed
4 0 2 mg Semaglutide (Injectable) Maximum dose — maintenance

Rationale

No washout period needed — can switch directly. Start semaglutide at a dose below the approximate equivalent to allow GI readjustment. Weight regain risk is real during transition — manage expectations.

Compounds Used

Related Tools

Track this regimen in Doseline

Adopt GLP-1 Switch — Tirzepatide → Semaglutide as a template, set reminders for every step, and log doses as you go. All free, all private.

Join the waitlist

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.

Doseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.